Platelet-Derived Growth Factor-BB Enhances Adipogenesis in Orbital Fibroblasts.

  title={Platelet-Derived Growth Factor-BB Enhances Adipogenesis in Orbital Fibroblasts.},
  author={Sita Virakul and Virgil A. S. H. Dalm and Dion Paridaens and Willem A. van den Bosch and Monique T. Mulder and Nattiya Hirankarn and Petrus Martin van Hagen and Willem A. Dik},
  journal={Investigative ophthalmology \& visual science},
  volume={56 9},
  • S. VirakulV. Dalm W. Dik
  • Published 1 August 2015
  • Biology, Medicine
  • Investigative ophthalmology & visual science
PURPOSE Platelet-derived growth factor (PDGF)-BB has been identified as important factor in pathogenesis of Graves' ophthalmopathy (GO). It stimulates proliferation, cytokine, and hyaluronan production, and thyrotropin receptor expression by orbital fibroblasts. Therefore, the PDGF-pathway has been proposed as a target for pharmacological intervention in GO. However, increased adipogenesis is another major pathological characteristic of GO and it is unknown whether this is affected by PDGF-BB… 

Figures from this paper

Basic Fibroblast Growth Factor Induces Adipogenesis in Orbital Fibroblasts: Implications for the Pathogenesis of Graves' Orbitopathy.

The hypothesis that multi-target directed therapy might be more efficient in the treatment of GO is supported, as the additive effect of bFGF and PDGF-BB on adipogenesis, along with the observed inhibitory effects of dasatinib and nintedanib, point at independent receptor-mediated effects.

Basic FGF and PDGF-BB synergistically stimulate hyaluronan and IL-6 production by orbital fibroblasts

Histamine induces NF-κB controlled cytokine secretion by orbital fibroblasts via histamine receptor type-1.

Update on pathogenesis and immunology of Graves’ ophthalmopathy

Increased hyaluronic acid production and fibroblast differentiation into adipocytes and myofibroblasts leads to development of graves’ ophthalmopathy, and the elevated number of molecular factors such as PDgF, iL1-β, icaM-1, osteopontin, ctLa-4, and tgF-β are discussed in the paper.

Histone Deacetylase 4 Controls Extracellular Matrix Production in Orbital Fibroblasts from Graves' Ophthalmopathy Patients.

The data indicated for the first time that altered HDAC4 regulation along with H3K9 hypoacetylation might represent a mechanism that contributes to excessive proliferation and extracellular matrix production by orbital fibroblasts in Graves' ophthalmopathy.

Hypoxia-Dependent HIF-1 Activation Impacts on Tissue Remodeling in Graves' Ophthalmopathy-Implications for Smoking.

Hypoxia impacts on tissue remodeling in GO by stimulating angiogenesis and adipogenesis through activation of HIF-1-dependent pathways in OFs and drug-targeted inhibition of Hif-1/VEGF may provide a therapeutic option to control tissue expansion in GO.

Transgenic PDGF-BB sericin hydrogel potentiates bone regeneration of BMP9-stimulated mesenchymal stem cells through a crosstalk of the Smad-STAT pathways

It is demonstrated that the PDGF-BB sericin hydrogel effectively augmented osteogenesis induced by bone morphogenetic protein (BMP9)-stimulated mesenchymal stem cells (MSCs) in vivo and in vitro, while inhibiting adipogenic differentiation.

Pingmu Decoction Induces Orbital Preadipocytes Apoptosis In Vitro

Pingmu Decoction could reduce orbital preadipocytes viability and induce apoptosis of mature adipocyte via Fas/Fas L signaling pathway and reduce lipid accumulation and downregulated the expression of PPAR γ and C/EBP α.

Integrative Analysis of Proteomics and DNA Methylation in Orbital Fibroblasts From Graves’ Ophthalmopathy

Comparisons of proteomics and DNA methylation data support that orbital fibroblasts from active GO are involved in inflammation, adipogenesis, and glycosaminoglycan production, while orbital fibrobasts from inactive disease are more skewed towards an active role in extracellular matrix remodeling.



Platelet-Derived Growth Factor: A Key Factor in the Pathogenesis of Graves' Ophthalmopathy and Potential Target for Treatment

The PDGF-system fulfills important roles in orbital fibroblast activation in both active and inactive GO, which supports a therapeutic rationale for blocking PDGF signaling in GO and Tyrosine kinase inhibitors (TKIs) may be candidates to targetPDGF signaling.

Platelet-derived growth factor-BB: a stimulus for cytokine production by orbital fibroblasts in Graves' ophthalmopathy.

PDGF-BB is a potent inducer of proinflammatory cytokines via the NF-kappaB pathway in orbital fibroblasts, whereas cytokine production by fibro Blasts from other anatomic locations showed a moderate response.

Mast Cell-derived Prostaglandin D2 Controls Hyaluronan Synthesis in Human Orbital Fibroblasts via DP1 Activation

It is reported here that mast cell-derived PGD2 is a key factor that promotes HA biosynthesis by orbital fibroblasts and Selectively targeting the production of PGD 2 and/or activation of DP1 may prevent pathological changes associated with TED.

The effects of tumour necrosis factor-alpha and interleukin1 on an in vitro model of thyroid-associated ophthalmopathy; contrasting effects on adipogenesis.

TNFalpha and IL1 stimulate ICAM1 expression and GAG production, but have opposite effects on adipogenesis in OFs in vitro, suggesting these agents may be the anti-cytokine treatment of choice for clinical trials in active TAO.

The tyrosine kinase inhibitor dasatinib effectively blocks PDGF-induced orbital fibroblast activation

  • S. VirakulV. Dalm W. Dik
  • Medicine, Biology
    Graefe's Archive for Clinical and Experimental Ophthalmology
  • 2014
Dasatinib may be a promising alternative to high-dose steroids in the treatment of Graves’ ophthalmopathy after significant and dose-dependent inhibition of PDGF-BB-induced orbital fibroblast proliferation, and hyaluronan and cytokine production.

Imatinib mesylate and AMN107 inhibit PDGF-signaling in orbital fibroblasts: a potential treatment for Graves' ophthalmopathy.

Imatinib mesylate and AMN107 inhibit orbital fibroblast proliferation and hyaluronan production induced by PDGF-BB; a factor highly expressed in orbital tissue from patients with GO; and should be considered as treatment candidates for GO.

Independent Adipogenic and Contractile Properties of Fibroblasts in Graves’ Orbitopathy: An In Vitro Model for the Evaluation of Treatments

A novel in vitro model testing the duality of the GO phenotype is established, demonstrating that a Thy-1-low population of GO cells underlies the adipogenic - but not the contractile - phenotype and confirming that the contractiles and adipogenic phenotypes are regulated by separate pathways.

Anti‐adipogenic effect of PDGF is reversed by PKC inhibition

PDGF treatment resulted in the persistence of PDGF receptor and PKCα expression, in contrast to the expected downregulation of both proteins that occurs during differentiation.

Evidence of adipocyte differentiation in human orbital fibroblasts in primary culture.

It is concluded that a subpopulation of orbital fibroblasts in culture is capable of adipocyte differentiation, and may represent the in vivo process that contributes to excess orbital adipose tissue volume in Graves' ophthalmopathy.

Stimulation of adipogenesis, peroxisome proliferator-activated receptor-γ (PPARγ), and thyrotropin receptor by PPARγ agonist in human orbital preadipocyte fibroblasts

Results suggest that TSHR expression in GO orbital preadipocyte fibroblasts is linked to adipogenesis, a leading cause of Graves’ ophthalmopathy.